Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.91 |
| ▸ | MGAM | O43451 | 1/20 | 0.91 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.91 |
| ▸ | SI | P14410 | 1/20 | 0.91 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.91 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.61 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10617187 | 0.93 | GAA (0.78) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL9761141 | 0.86 | GAA (0.67) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL9518606 | 0.83 | GAA (0.64) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL10617443 | 0.81 | GAA (0.60) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL9504286 | 0.80 | GAA (0.59) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL10617365 | 0.80 | GAA (0.58) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL10617892 | 0.80 | GAA (0.58) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL10617898 | 0.80 | GAA (0.58) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL10617251 | 0.77 | GAA (0.56) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL10621732 | 0.77 | GAA (0.55) | GAAMGAMAMY1ASIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 570 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330188-A1 | PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT AND/OR PREVENTION OF DIABETES | INSPHERO AG (CH) | 2023-10-19 | — | — | US | claimed |
| EP-4225296-A1 | PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT AND/OR PREVENTION OF DIABETES | Insphero AG (CH) | 2023-08-16 | — | — | EP | claimed |
| WO-2022074057-A1 | PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT AND/OR PREVENTION OF DIABETES | INSPHERO AG (CH) | 2022-04-14 | — | — | WO | claimed |
| EP-3981401-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT AND/OR PREVENTION OF DIABETES COMPRISING A CALCIUM CHANNEL BLOCKING AGENT AND AN INCRETIN MIMETIC | InSphero AG (CH) | 2022-04-13 | — | — | EP | claimed |
| EP-3621593-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2020-03-18 | — | — | EP | claimed |
| WO-2019194866-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2019-10-10 | — | — | WO | claimed |
| US-20190231786-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | CARDIX Therapeutics, LLC | 2019-08-01 | — | — | US | claimed |
| CN-109890366-A | Combination medicine for treating cardiovascular diseases and preparation and use methods thereof | 美进医药公司 | 2019-06-14 | — | — | CN | claimed |
| US-20190070184-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2019-03-07 | — | — | US | claimed |
| WO-2018208723-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2018-11-15 | — | — | WO | claimed |
| WO-2002043806-A2 | IN VIVO DELIVERY METHODS AND COMPOSITIONS | RHEOLOGICS, INC (US) | 2002-06-06 | — | — | WO | claimed |
| US-20020061835-A1 | Administering a drug to a human which is pharmaceutically effective to regulate at least one of the blood parameters used to adjust distribution of the drug through the bloodstream | RHEOLOGICS, INC. | 2002-05-23 | — | — | US | claimed |
| US-20020042405-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | SCHUH JOSEPH R (US) | 2002-04-11 | — | — | US | claimed |
| US-20020032149-A1 | Monitoring blood flow parameter of bloodstream, administering substance to organism such that an amount of substance enters bloodstream; distributing portion of amount ofsubstance target within organism | RHEOLOGICS, INC. | 2002-03-14 | — | — | US | claimed |
| WO-2002009761-A2 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND CALCIUM CHANNEL BLOCKER COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | PHARMACIA CORPORATION (US) | 2002-02-07 | — | — | WO | claimed |
| US-20010044584-A1 | In vivo delivery methods and compositions | RHEOLOGICS, INC. | 2001-11-22 | — | — | US | claimed |
| EP-0639986-A1 | TOPICAL OPHTHALMIC COMPOSITIONS COMPRISING A COMBINATION OF CALCIUM ANTAGONISTS WITH KNOWN ANTIGLAUCOMA AGENTS | ALCON LABORATORIES, INC. (US) | 1995-03-01 | — | — | EP | claimed |
| WO-1993023082-A1 | TOPICAL OPHTHALMIC COMPOSITIONS COMPRISING A COMBINATION OF CALCIUM ANTAGONISTS WITH KNOWN ANTIGLAUCOMA AGENTS | ALCON LABORATORIES, INC. (US) | 1993-11-25 | — | — | WO | claimed |
| CN-1049455-A | Improve the new oral medicament of bioavailability | DELAGRANGE LAB (FR) | 1991-02-27 | — | — | CN | claimed |
| EP-0301133-A2 | Long acting formulation | SYNTEX (U.S.A.) INC. (US) | 1989-02-01 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330188-A1 | PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT AND/OR PREVENTION OF DIABETES | IAPP, SLC5A2, GLP1R | GAA 869/4885MGAM 521/4885AMY1A 878/4885 |
| US-20020042405-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | KCNN4, NR3C2, EDNRA | GAA 3672/4885MGAM 3184/4885AMY1A 2463/4885 |
| US-20190070184-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | ADRB2, ADRA2C, ADRB1 | GAA 1649/4885MGAM 4386/4885AMY1A 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.